Written and maintained by CASRAI Editorial Board
Last updated
INESSS — the Institut national d’excellence en santé et en services sociaux — is Quebec’s own health technology assessment (HTA) body. It’s easy to assume CDA-AMC, the national HTA body used by the rest of Canada, covers Quebec too; it doesn’t. Quebec runs its own parallel assessment process through INESSS rather than relying solely on CDA-AMC’s recommendation, and that distinction matters for anyone tracking a drug or health technology’s path to public coverage in Quebec specifically.
INESSS’s mandate and mission
INESSS was established January 19, 2011, under Quebec’s Act respecting the Institut national d’excellence en santé et en services sociaux, replacing two predecessor bodies: the Conseil du médicament (which had handled drug evaluation) and AETMIS (Agence d’évaluation des technologies et des modes d’intervention en santé, which had handled health technology assessment). Consolidating both functions into one institute was the point: INESSS’s stated mission is to promote clinical excellence and the efficient use of resources across Quebec’s health and social services sector. Its governance includes a Board of Directors, a Scientific Council, an Advisory Panel, and specialized committees (including a dedicated rare-diseases committee), and it operates under stated values of independence, scientific rigour, transparency, integrity, and equity for users.
What INESSS evaluates
INESSS’s mandate is broader than drugs alone. It covers pharmaceutical products and optimal medication use, health technologies and medical procedures, medical protocols and prescriptions, cancerology and other specialized clinical areas, and — distinct from the rest of Canada’s HTA bodies, which are drug- and technology-focused — social services, including disability supports, mental health and addiction services, and seniors’ support. That social-services scope is a real structural difference from CDA-AMC, which has no equivalent mandate.
How INESSS evaluates a drug listing request
For drug listing requests specifically, INESSS’s Constituent Act sets out four evaluation criteria: therapeutic value (assessed first — if a drug doesn’t clear this bar, INESSS notifies the Minister accordingly rather than proceeding further), price reasonableness, cost-effectiveness, and system impact (the effect on public health and on the basic drug insurance plan’s overall purpose). The process runs 90 to 180 days and follows a defined sequence: the manufacturer files a two-month advance notice, a seven-week public consultation period opens for citizens, patients, and professionals to comment, the manufacturer submits its full clinical and pharmacoeconomic evidence, INESSS’s professional staff and standing scientific committee review that evidence (drawing on outside expert input where needed), the resulting recommendation goes to INESSS’s Board of Directors for ratification, and the Minister of Health and Social Services makes the final listing decision.
From INESSS recommendation to a Quebec formulary listing
Like a CDA-AMC recommendation, an INESSS recommendation is advisory to the Minister rather than self-executing. Once the Minister decides, INESSS’s “Notices to the Minister” are published following a 30-day moratorium, after which Quebec’s health insurance agency, RAMQ (Régie de l’assurance maladie du Québec), updates the standard medication list and the institutional medication list that Quebec’s public drug plan actually pays against. The same gap that exists nationally between a CDA-AMC recommendation and a completed pCPA price negotiation and provincial listing applies structurally in Quebec too: a positive INESSS recommendation is a necessary step toward coverage, not the coverage decision itself.
How INESSS relates to CDA-AMC and the rest of Canada’s HTA landscape
INESSS and CDA-AMC are structurally parallel, not hierarchical — INESSS doesn’t report to or defer to CDA-AMC, and a CDA-AMC recommendation doesn’t automatically apply in Quebec. A manufacturer seeking to have a drug reimbursed across Canada typically has to go through both processes: CDA-AMC’s national reimbursement review for the rest of the country, and INESSS’s separate evaluation for Quebec specifically, each with its own timeline, evidence submission, and committee review. This is the same “fragmented multi-payer system” dynamic that distinguishes Canada’s HTA landscape from a single-payer model like the UK’s NICE technology appraisal process — except in Canada it plays out at both the federal-versus-provincial level and, within Quebec specifically, at the INESSS-versus-rest-of-Canada level.
Frequently asked questions
What does INESSS stand for? Institut national d’excellence en santé et en services sociaux — the National Institute of Excellence in Health and Social Services.
Is INESSS the same as CDA-AMC? No. Both perform health technology assessment, but INESSS is Quebec-specific and evaluates for Quebec’s public drug plan; CDA-AMC’s recommendations cover the rest of Canada. A drug needs a separate INESSS evaluation to reach Quebec’s formulary even after a positive CDA-AMC recommendation elsewhere.
Does INESSS only evaluate drugs? No. Its mandate also covers health technologies and medical procedures, medical protocols, cancerology, and social services including disability, mental health and addiction, and seniors’ supports — broader than the drug-and-device focus of most other HTA bodies.
How long does an INESSS drug evaluation take? INESSS states the process runs 90 to 180 days from advance notice through Ministerial decision, including a mandatory seven-week public consultation period.
